Diagnosis and Treatment of Mitochondrial Myopathies
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Mitochondrial myopathies are progressive muscle conditions caused primarily by the impairment of oxidative phosphorylation (OXPHOS) in the mitochondria. This causes a deficit in energy production in the form of adenosine triphosphate (ATP), particularly in skeletal muscle. The diagnosis of mitochondrial myopathy is reliant on the combination of numerous techniques including traditional histochemical, immunohistochemical, and biochemical testing combined with the fast-emerging molecular genetic techniques, namely next-generation sequencing (NGS). This has allowed for the diagnosis to become more effective in terms of determining causative or novel genes. However, there are currently no effective or disease-modifying treatments available for the vast majority of patients with mitochondrial myopathies. Existing therapeutic options focus on the symptomatic management of disease manifestations. An increasing number of clinical trials have investigated the therapeutic effects of various vitamins, cofactors, and small molecules, though these trials have failed to show definitive outcome measures for clinical practice thus far. In addition, new molecular strategies, specifically mtZFNs and mtTALENs, that cause beneficial heteroplasmic shifts in cell lines harboring varying pathogenic mtDNA mutations offer hope for the future. Moreover, recent developments in the reproductive options for patients with mitochondrial myopathies mean that for some families, the possibility of preventing transmission of the mutation to the next generation is now possible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cantó, C., Houtkooper, R. H., Pirinen, E., Youn, D. Y., Oosterveer, M. H., Cen, Y., Fernandez-Marcos, P. J., Yamamoto, H., Andreux, P. A., Cettour-Rose, P., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.022 · Cited by 1,238 · cited 3×
“NAD+ which has been shown to induce mitochondrial biogenesis, thus increasing oxidative ATP production capacity [37, 38].”
BackgroundResultInfluentialBieganowski, P., & Brenner, C. (2004) · Cell · doi:10.1016/s0092-8674(04)00416-7 · Cited by 750
A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy.
Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., et al. (2011) · Brain · doi:10.1093/brain/awr170 · Cited by 578
Bua, E., Johnson, J., Herbst, A., Delong, B., McKenzie, D., Salamat, S., & Aiken, J. M. (2006) · The American Journal of Human Genetics · doi:10.1086/507132 · Cited by 442
Suomalainen, A., Elo, J. M., Pietiläinen, K. H., Hakonen, A. H., Sevastianova, K., Korpela, M., Isohanni, P., Marjavaara, S. K., Tyni, T., Kiuru-Enari, S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70155-7 · Cited by 427 · cited 1×
“FGF-21 levels are seen to be raised in patients who have muscle involvement, and thus, in cases with suspected mitochondrial myopathies, the noninvasive measurement of the growth factor acts as a helpful and sensitive first-line investigation in the diagnostic process [24, 25].”
BackgroundEffective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3
Khan, N. A., Auranen, M., Paetau, I., Pirinen, E., Euro, L., Forsström, S., Pasila, L., Velagapudi, V., Carroll, C. J., Auwerx, J., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201403943 · Cited by 385
Tyynismaa, H., Mjosund, K. P., Wanrooij, S., Lappalainen, I., Ylikallio, E., Jalanko, A., Spelbrink, J. N., Paetau, A., & Suomalainen, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505551102 · Cited by 342
Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders
Yatsuga, S., Fujita, Y., Ishii, A., Fukumoto, Y., Arahata, H., Kakuma, T., Kojima, T., Ito, M., Tanaka, M., Saiki, R., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24506 · Cited by 293
The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients
Taivassalo, T. (2003) · Brain · doi:10.1093/brain/awg028 · Cited by 282
Taivassalo, T., Gardner, J. L., Taylor, R. W., Schaefer, A. M., Newman, J., Barron, M. J., Haller, R. G., & Turnbull, D. M. (2006) · Brain · doi:10.1093/brain/awl282 · Cited by 220
Self-citation
Research works printed but not linked: 62
- Gorman, 2016, Mitochondrial diseases, Nat Rev Dis Primers, 2, 10.1038/nrdp.2016.80 · DOI · Paper page
- Shoffner, 1989, Spontaneous Kearns-Sayre/chronic external ophthalmoplegia plus syndrome associated with a mitochondrial DNA deletion: a slip-replication model and metabolic therapy, Proc Natl Acad Sci U S A, 86, 7952, 10.1073/pnas.86.20.7952 · DOI · Paper page
- Rossignol, 2003, Mitochondrial threshold effects, Biochem J, 370, 751, 10.1042/bj20021594 · DOI · Paper page
- Sommerville, 2014, Adult-onset Mendelian PEO Associated with Mitochondrial Disease, J Neuromuscul Dis, 1, 119, 10.3233/JND-140041 · DOI
- Gorman, 2015, Perceived fatigue is highly prevalent and debilitating in patients with mitochondrial disease, Neuromuscul Disord, 25, 563, 10.1016/j.nmd.2015.03.001 · DOI · Paper page
- Alston, 2017, The genetics and pathology of mitochondrial disease, J Pathol, 241, 236, 10.1002/path.4809 · DOI · Paper page
- Moraes, 1992, The mitochondrial tRNA(Leu(UUR)) mutation in mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes (MELAS): genetic, biochemical, and morphological correlations in skeletal muscle, Am J Hum Genet, 50, 934
- Campbell, 2014, Dissecting the mechanisms underlying the accumulation of mitochondrial DNA deletions in human skeletal muscle, Hum Mol Genet, 23, 4612, 10.1093/hmg/ddu176 · DOI
- Ahmed, 2017, Using a quantitative quadruple immunofluorescent assay to diagnose isolated mitochondrial Complex I deficiency, Sci Rep, 7, 10.1038/s41598-017-14623-2 · DOI
- Rocha, 2015, A novel immunofluorescent assay to investigate oxidative phosphorylation deficiency in mitochondrial myopathy: understanding mechanisms and improving diagnosis, Sci Rep, 5, 10.1038/srep15037 · DOI · Paper page
- Bernier, 2002, Diagnostic criteria for respiratory chain disorders in adults and children, Neurology, 59, 1406, 10.1212/01.WNL.0000033795.17156.00 · DOI · Paper page
- Taylor, 2014, Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies, JAMA, 312, 68, 10.1001/jama.2014.7184 · DOI · Paper page
- Frazier, 2017, Mitochondrial energy generation disorders: genes, mechanisms and clues to pathology, J Biol Chem
- Grady JP, Pickett SJ. mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease. 10(6) (2018). · DOI · Paper page
- Calvo, 2012, Molecular Diagnosis of Infantile Mitochondrial Disease with Targeted Next-Generation Sequencing, Sci Transl Med, 4, 118ra110, 10.1126/scitranslmed.3003310 · DOI · Paper page
- Calvo, 2006, Systematic identification of human mitochondrial disease genes through integrative genomics, Nat Genet, 38, 576, 10.1038/ng1776 · DOI · Paper page
- McFarland, 2010, A neurological perspective on mitochondrial disease, Lancet Neurol, 9, 829, 10.1016/S1474-4422(10)70116-2 · DOI · Paper page
- Grady, 2014, Disease progression in patients with single, large-scale mitochondrial DNA deletions, Brain, 137, 323, 10.1093/brain/awt321 · DOI
- Volpi, 2011, Metabolic myopathies: functional evaluation by different exercise testing approaches, Musculoskelet Surg, 95, 59, 10.1007/s12306-011-0096-9 · DOI
- Tarnopolsky, 2004, Clinical variability in maternally inherited leber hereditary optic neuropathy with the G14459A mutation, Am J Med Genet A, 124a, 372, 10.1002/ajmg.a.20449 · DOI
- Lehtonen, 2016, FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders, Neurology, 87, 2290, 10.1212/WNL.0000000000003374 · DOI · Paper page
- Morovat, 2017, Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical Practice, J Clin Med, 6, 80, 10.3390/jcm6080080 · DOI
- Fujita, 2015, GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases, Mitochondrion, 20, 34, 10.1016/j.mito.2014.10.006 · DOI · Paper page
- Taivassalo, 2002, Venous oxygen levels during aerobic forearm exercise: An index of impaired oxidative metabolism in mitochondrial myopathy, Ann Neurol, 51, 38, 10.1002/ana.10027 · DOI · Paper page
- Horvath, 2012, Adult-onset cerebellar ataxia due to mutations in CABC1/ADCK3, J Neurol Neurosurg Psychiatry, 83, 174, 10.1136/jnnp-2011-301258 · DOI
- Glover Elisa, 2010, A randomized trial of coenzyme Q10 in mitochondrial disorders, Muscle Nerve, 42, 739, 10.1002/mus.21758 · DOI · Paper page
- Stacpoole, 2012, Design and Implementation of the First Randomized Controlled Trial of Coenzyme Q(10) in Children with Primary Mitochondrial Diseases, Mitochondrion, 12, 623, 10.1016/j.mito.2012.09.005 · DOI
- Giorgio, 2012, The effects of idebenone on mitochondrial bioenergetics, Biochim Biophys Acta, 1817, 363, 10.1016/j.bbabio.2011.10.012 · DOI · Paper page
- Yatsuga, 2012, Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice, Hum Mol Genet, 21, 526, 10.1093/hmg/ddr482 · DOI · Paper page
- Viscomi, 2011, In vivo correction of COX deficiency by activation of the AMPK/PGC-1alpha axis, Cell Metab, 14, 80, 10.1016/j.cmet.2011.04.011 · DOI · Paper page
- Reisman, 2014, Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis, Radiat Res, 181, 512, 10.1667/RR13578.1 · DOI · Paper page
- Shen, 2008, R-alpha-lipoic acid and acetyl-L-carnitine complementarily promote mitochondrial biogenesis in murine 3T3-L1 adipocytes, Diabetologia, 51, 165, 10.1007/s00125-007-0852-4 · DOI
- Ahola-Erkkila, 2010, Ketogenic diet slows down mitochondrial myopathy progression in mice, Hum Mol Genet, 19, 1974, 10.1093/hmg/ddq076 · DOI · Paper page
- Santra, 2004, Ketogenic treatment reduces deleted mitochondrial DNAs in cultured human cells, Ann Neurol, 56, 662, 10.1002/ana.20240 · DOI
- Ahola, 2016, Modified Atkins diet induces subacute selective ragged-red-fiber lysis in mitochondrial myopathy patients, EMBO Mol Med, 8, 1234, 10.15252/emmm.201606592 · DOI · Paper page
- Alam, 2015, A mitochondrial therapeutic reverses visual decline in mouse models of diabetes, Dis Model Mech, 8, 701
- Szeto, 2014, Serendipity and the Discovery of Novel Compounds That Restore Mitochondrial Plasticity, Clin Pharmacol Ther, 96, 672, 10.1038/clpt.2014.174 · DOI · Paper page
- Siegel, 2013, Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice, Aging Cell, 12, 763, 10.1111/acel.12102 · DOI · Paper page
- Karaa, 2018, Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy, Neurology, 90, e1212, 10.1212/WNL.0000000000005255 · DOI · Paper page
- Koene, 2017, KH176 under development for rare mitochondrial disease: a first in man randomized controlled clinical trial in healthy male volunteers, Orphanet J Rare Dis, 12, 163, 10.1186/s13023-017-0715-0 · DOI
- Taivassalo, 2001, Aerobic conditioning in patients with mitochondrial myopathies: physiological, biochemical, and genetic effects, Ann Neurol, 50, 133, 10.1002/ana.1050 · DOI · Paper page
- Cejudo, 2005, Exercise training in mitochondrial myopathy: a randomized controlled trial, Muscle Nerve, 32, 342, 10.1002/mus.20368 · DOI · Paper page
- Murphy, 2008, Resistance training in patients with single, large-scale deletions of mitochondrial DNA, Brain, 131, 2832, 10.1093/brain/awn252 · DOI · Paper page
- Bates, 2013, Defining cardiac adaptations and safety of endurance training in patients with m.3243A>G-related mitochondrial disease, Int J Cardiol, 168, 3599, 10.1016/j.ijcard.2013.05.062 · DOI
- Zeviani, 2008, Train, train, train! No pain, just gain, Brain, 131, 2809, 10.1093/brain/awn264 · DOI
- Minczuk, 2008, Development of a single-chain, quasi-dimeric zinc-finger nuclease for the selective degradation of mutated human mitochondrial DNA, Nucleic Acids Res, 36, 3926, 10.1093/nar/gkn313 · DOI · Paper page
- Bacman, 2014, The Use of Mitochondria-Targeted Endonucleases to Manipulate mtDNA, Methods Enzymol, 547, 373, 10.1016/B978-0-12-801415-8.00018-7 · DOI
- Gammage, 2014, Mitochondrially targeted ZFNs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations, EMBO Mol Med, 6, 458, 10.1002/emmm.201303672 · DOI · Paper page
- Hashimoto, 2015, MitoTALEN: A General Approach to Reduce Mutant mtDNA Loads and Restore Oxidative Phosphorylation Function in Mitochondrial Diseases, Mol Ther, 23, 1592, 10.1038/mt.2015.126 · DOI · Paper page
- Gammage, 2016, Near-complete elimination of mutant mtDNA by iterative or dynamic dose-controlled treatment with mtZFNs, Nucleic Acids Res, 44, 7804, 10.1093/nar/gkw676 · DOI
- Reddy, 2015, Selective elimination of mitochondrial mutations in the germline by genome editing, Cell, 161, 459, 10.1016/j.cell.2015.03.051 · DOI · Paper page
- Garone, 2014, Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency, EMBO Mol Med, 6, 1016, 10.15252/emmm.201404092 · DOI
- Nesbitt, 2014, A national perspective on prenatal testing for mitochondrial disease, Eur J Hum Genet, 22, 10.1038/ejhg.2014.35 · DOI
- Smeets, 2015, Preventing the transmission of mitochondrial DNA disorders using prenatal or preimplantation genetic diagnosis, Ann N Y Acad Sci, 1350, 29, 10.1111/nyas.12866 · DOI
- Craven, 2010, Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease, Nature, 465, 82, 10.1038/nature08958 · DOI · Paper page
- Lyndsey, 2017, Recent Advances in Mitochondrial Disease, Annu Rev Genomics Hum Genet, 18, 257, 10.1146/annurev-genom-091416-035426 · DOI · Paper page
- Yamada, 2016, Genetic Drift Can Compromise Mitochondrial Replacement by Nuclear Transfer in Human Oocytes, Cell Stem Cell, 18, 749, 10.1016/j.stem.2016.04.001 · DOI · Paper page
- Kang, 2016, Mitochondrial replacement in human oocytes carrying pathogenic mitochondrial DNA mutations, Nature, 540, 270, 10.1038/nature20592 · DOI · Paper page
- Hyslop, 2016, Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease, Nature, 534, 383, 10.1038/nature18303 · DOI · Paper page
- Greenfield, 2017, Assisted reproductive technologies to prevent human mitochondrial disease transmission, Nat Biotechnol, 35, 10.1038/nbt.3997 · DOI
- Craven, 2016, Research into Policy: A Brief History of Mitochondrial Donation, Stem Cells, 34, 265, 10.1002/stem.2221 · DOI
- Gorman, 2015, Mitochondrial donation–how many women could benefit?, N Engl J Med, 372, 885, 10.1056/NEJMc1500960 · DOI
Cited by
Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances
Xu, X., Pang, Y., & Fan, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02253-4 · Cited by 800
Codon optimization is an essential parameter for the efficient allotopic expression of mtDNA genes
Lewis, C. J., Dixit, B., Batiuk, E., Hall, C. J., O'Connor, M. S., & Boominathan, A. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101429 · Cited by 20
“to combat symptoms [11,12], selective mitophagy to remove damaged”
BackgroundPorcelli, S., Grassi, B., Poole, D. C., & Marzorati, M. (2019) · Current Opinion in Physiology · doi:10.1016/j.cophys.2019.05.011 · Cited by 13
Chatel, B., Ducreux, S., Harhous, Z., Bendridi, N., Varlet, I., Ogier, A. C., Bernard, M., Gondin, J., Rieusset, J., Westerblad, H., et al. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.048981 · Cited by 8
Metadata
- Authors
- Ahmed, S. T., Craven, L., Russell, O. M., Turnbull, D. M., & Vincent, A. E.
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 15
- Issue
- 4
- Pages
- 943-953
- ISSN
- 1878-7479 (ISSN-L)
- OpenAlex
- W2900029109
- Cited by
- 152
- References
- 14
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 37 d)
- Funders
- Wellcome Trust (203105/Z/16/Z)
- Medical Research Council (MR/L016354/1)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnosis and Treatment of Mitochondrial Myopathies. https://app.cochat.ai/papers/10.1007/s13311-018-00674-4
- The paper
- Ahmed, S. T., Craven, L., Russell, O. M., Turnbull, D. M., & Vincent, A. E. (2018). Diagnosis and Treatment of Mitochondrial Myopathies. Neurotherapeutics. https://doi.org/10.1007/s13311-018-00674-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.